Payment overview · 2025
General Payments
$957.65
10 reported records · 8 companies
Healthcare provider profile · identity verified
Dawna Rae Hernandez
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TUCSON, AZ · NPI 1295340651
Verified facts
What the public records show
CMS Open Payments records show Dawna Rae Hernandez received $957.65 in general payments during 2025 across 10 reported records.
Medtronic, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 230 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$246.41 | 25.7% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $125.00 | 13.1% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $124.98 | 13.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.59 | 13.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $112.09 | 11.7% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $110.17 | 11.5% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.38 | 7.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.03 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $957.65 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $153.55 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Jakafi Normalized: jakafi |
Drug | Incyte Corporation | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.59 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $112.09 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $110.17 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $92.86 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $72.38 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $42.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 230 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
230 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 77 |
| Atorvastatin Calcium | Atorvastatin Calcium | 362 | 80 |
| Trazodone Hcl | Trazodone Hcl | 335 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 329 | 52 |
| Furosemide | Furosemide | 326 | 73 |
| Gabapentin | Gabapentin | 283 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 280 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 40 |
| Mirtazapine | Mirtazapine | 250 | 47 |
| Potassium Chloride | Potassium Chloride | 239 | 50 |
| Eliquis | Apixaban | 230 | 52 |
| Losartan Potassium | Losartan Potassium | 222 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 54 |
| Sertraline Hcl | Sertraline Hcl | 211 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 36 |
| Lisinopril | Lisinopril | 198 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 42 |
| Divalproex Sodium | Divalproex Sodium | 175 | 27 |
| Omeprazole | Omeprazole | 156 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 35 |
| Metformin Hcl | Metformin Hcl | 140 | 29 |
| Memantine Hcl | Memantine Hcl | 131 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 24 |
| Tramadol Hcl | Tramadol Hcl | 124 | 39 |
| Donepezil Hcl | Donepezil Hcl | 118 | 20 |
| Simvastatin | Simvastatin | 101 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 99 | 66 |
| Montelukast Sodium | Montelukast Sodium | 97 | 26 |
| Buspirone Hcl | Buspirone Hcl | 96 | 26 |
| Finasteride | Finasteride | 93 | 14 |
| Carvedilol | Carvedilol | 90 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 88 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 87 | 61 |
| Famotidine | Famotidine | 78 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 25 |
| Levetiracetam | Levetiracetam | 77 | 12 |
| Baclofen | Baclofen | 70 | 17 |
| Xarelto | Rivaroxaban | 68 | 12 |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 47 |
| Nystatin | Nystatin | 56 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 39 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Lorazepam | Lorazepam | 49 | 21 |
| Latanoprost | Latanoprost | 47 | 13 |
| Spironolactone | Spironolactone | 47 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 12 |
| Allopurinol | Allopurinol | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 30 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 38 | 13 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 30 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 14 |
| Amoxicillin | Amoxicillin | 28 | 21 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Prednisone | Prednisone | 26 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | 11 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Valsartan | Valsartan | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | 11 |
| Lacosamide | Lacosamide | 14 | suppressed |
| Nystop | Nystatin | 14 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Depakote Sprinkle | Divalproex Sodium | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $957.65 · 10 records | Medtronic, Inc. | AUSTEDO XR, Auvelity, BRIUMVI, ELIQUIS, Jakafi, SYMPLICITY G3, SYNCHROMEDII, VYVGART, ZENPEP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error